Biologics for the Treatment of Juvenile Idiopathic Arthritis

Title:Biologics for the Treatment of Juvenile Idiopathic Arthritis

Volume: 25 Issue: 42

Author(s): Dimitri Poddighe*, Micol Romano, Maurizio Gattinara and Valeria Gerloni

Affiliation:

• Department of Medicine, School of Medicine, Nazarbayev University, Kerei-Zhanibek Str. 5/1, Astana, 010000,Kazakhstan

Keywords: Biologics, JIA, clinical evidence, immunology, pharmacodynamics, pharmacokinetics.

Abstract: Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate the specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidence regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.

Cite this article as:

Poddighe Dimitri *, Romano Micol , Gattinara Maurizio and Gerloni Valeria , Biologics for the Treatment of Juvenile Idiopathic Arthritis, Current Medicinal Chemistry 2018; 25 (42) . https://dx.doi.org/10.2174/0929867325666180522085716